IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Related Articles
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
Sacituzumab govitecan (SG), a Trop-2-directed antibody–drug conjugate, demonstrated efficacy and manageable toxicity in the phase II TROPHY-U-01 study in pretreated advanced urothelial carcinoma (aUC). We…
Pertuzumab Retreatment in HER2-Positive Locally Advanced/Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed…
Trump administration caps indirect costs at 15%, inviting injunctions, congressional scrutiny The move could gut academic cancer research – The Cancer Letter
Late on Friday, Feb. 7, the Trump administration announced that indirect costs paid on grants to U.S. medical research institutions would—starting immediately—henceforth be capped at…
ASTCT and CIBMTR 2025
Fred Hutch scientists are presenting new research findings at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR on February 12-15, 2025. The ASTCT…
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Olaparib did not reveal radiographic response for patients with isocitrate dehydrogenase 1 (IDH1)– and IDH2-mutant cholangiocarcinoma. However, prolonged disease control was seen in a subset…
Tandem Meetings Home
The Tandem Meetings are a premier event in the evolving hematopoietic cell transplantation (HCT) and cellular therapy field. Through the scientific program, attendees gain access…
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel
Nature Reviews Cancer – In their Review article, Fuchs and colleagues discuss how a single or a few mutations in adult cells can lead to…
Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.
MD Anderson Research Highlights for February 10, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Webmeeting Pós ASCO GI 2025
Este site utiliza cookies para melhorar a experiência do usuário e oferecer conteúdo adaptado aos seus interesses. Ao continuar navegando você concorda com a política…
